Natterman Noscasan (Noscapine Hydrochloride)

Noscapine Hydrochloride, the active ingredient in Natterman Noscasan, is an antitussive presented as an oral formulation for oral use. It suppresses cough by acting on the central cough reflex and is indicated for patients experiencing dry, non‑productive cough.

GNH USA supplies Natterman Noscasan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noscapine Hydrochloride is an antitussive that acts on the central cough reflex pathway to reduce coughing.

- Acute cough: provides relief from sudden onset dry cough. - Chronic cough: helps decrease frequency of persistent non‑productive cough. - Cough associated with upper respiratory infections: eases irritation‑driven cough.

Noscapine Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: transient light‑headedness. - Drowsiness: increased sleepiness. - Headache: mild to moderate pain. - Gastrointestinal discomfort: abdominal cramping or loose stools.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hematologic abnormalities: rare cases of neutropenia or thrombocytopenia.

When prescribing or dispensing Noscapine Hydrochloride, consider the following precautions. - Assess renal function: adjust use in severe renal impairment. - Monitor hepatic health: avoid in patients with active liver disease. - Caution with CNS depressants: may enhance drowsiness. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Use during pregnancy only if clearly needed: limited safety data. - Store at ambient temperature: keep in original packaging, protect from moisture.

Noscapine Hydrochloride can interact with other medicines; be aware of the following.

Major Interactions (Avoid): - Other antitussives: combined use may cause excessive suppression of cough. - Strong CNS depressants (e.g., benzodiazepines): increased sedation risk. - MAO inhibitors: potential for heightened central effects.

Moderate Interactions (Monitor Closely): - Alcohol: may intensify drowsiness. - Antihistamines: additive sedation. - Opioid analgesics: possible enhanced respiratory depression.